LSK BioPharma and Jiangsu Hengrui Medicine Announce Enrollment of The First Patient in a Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Rivoceranib (Apatinib)
SALT LAKE CITY, USA, June 30, 2019 LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in China, today announced the first patient has been enrolled in
